Press Releases Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E. Other stock markets 03:59:51 2024-05-31 pm EDT			5-day change	1st Jan Change
1.71 ^CAD	-1.16%		-3.93%	-20.09%

May. 23	Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	MT
May. 23	Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors	May. 23	AQ
Theratechnologies Reports on its Annual Meeting of Shareholders	May. 09	AQ
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting	May. 02	AQ
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	Apr. 15	AQ
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 11	AQ
Theratechnologies: Fiscal Q1 Earnings Snapshot	Apr. 10	AQ
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	Apr. 10	AQ
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	Apr. 08	AQ
Theratechnologies Appoints Elina Tea to its Board of Directors	Apr. 05	AQ
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update	Apr. 03	AQ
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform	Mar. 28	AQ
Theratechnologies Announces Update on its Preclinical Oncology Research Program	Mar. 22	AQ
Theratechnologies Appoints Jordan Zwick to its Board of Directors	Mar. 21	AQ
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	Mar. 21	AQ
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau	Feb. 29	AQ
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA	Feb. 27	AQ
Theratechnologies: Fiscal Q4 Earnings Snapshot	Feb. 21	AQ
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance	Feb. 21	AQ
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action	Feb. 20	AQ
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer	Feb. 15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Theratechnologies Inc.

Equities

TH

CA88338H7040

Press Releases

Filters